ARDELYX INC (ARDX) Stock Fundamental Analysis
NASDAQ:ARDX • US0396971071
6.56 USD
0 (0%)
At close: Feb 25, 2026
6.55 USD
-0.01 (-0.15%)
After Hours: 2/25/2026, 8:00:01 PM
Overall ARDX gets a fundamental rating of 3 out of 10. We evaluated ARDX against 521 industry peers in the Biotechnology industry. ARDX may be in some trouble as it scores bad on both profitability and health. ARDX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- ARDX had negative earnings in the past year.
- ARDX had a negative operating cash flow in the past year.
- ARDX had negative earnings in each of the past 5 years.
- ARDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ARDX's Return On Assets of -12.28% is amongst the best of the industry. ARDX outperforms 82.73% of its industry peers.
- ARDX has a Return On Equity of -36.90%. This is in the better half of the industry: ARDX outperforms 71.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.28% | ||
| ROE | -36.9% | ||
| ROIC | N/A |
ROA(3y)-14.49%
ROA(5y)-36.87%
ROE(3y)-33.03%
ROE(5y)-71.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ARDX has a Gross Margin of 90.29%. This is amongst the best in the industry. ARDX outperforms 92.71% of its industry peers.
- In the last couple of years the Gross Margin of ARDX has declined.
- ARDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y-1.65%
2. Health
2.1 Basic Checks
- ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ARDX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, ARDX has more shares outstanding
- ARDX has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.46, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
- ARDX has a Altman-Z score of 1.46. This is in the better half of the industry: ARDX outperforms 64.49% of its industry peers.
- A Debt/Equity ratio of 1.21 is on the high side and indicates that ARDX has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.21, ARDX is not doing good in the industry: 76.01% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.46 |
ROIC/WACCN/A
WACC8.59%
2.3 Liquidity
- A Current Ratio of 4.31 indicates that ARDX has no problem at all paying its short term obligations.
- ARDX has a Current ratio (4.31) which is in line with its industry peers.
- ARDX has a Quick Ratio of 4.11. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 4.11, ARDX is in line with its industry, outperforming 50.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.31 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
- ARDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.37%.
- The Revenue has grown by 22.09% in the past year. This is a very strong growth!
- ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 121.91% yearly.
EPS 1Y (TTM)-53.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y98.4%
Revenue growth 5Y121.91%
Sales Q2Q%7.82%
3.2 Future
- Based on estimates for the next years, ARDX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.74% on average per year.
- The Revenue is expected to grow by 27.17% on average over the next years. This is a very strong growth
EPS Next Y157.24%
EPS Next 2Y120.07%
EPS Next 3Y74.4%
EPS Next 5Y60.74%
Revenue Next Year35.32%
Revenue Next 2Y34.72%
Revenue Next 3Y24.52%
Revenue Next 5Y27.17%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
- With a Price/Forward Earnings ratio of 45.84, ARDX can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, ARDX is valued cheaper than 90.79% of the companies in the same industry.
- ARDX is valuated expensively when we compare the Price/Forward Earnings ratio to 28.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.84 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ARDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ARDX's earnings are expected to grow with 74.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y120.07%
EPS Next 3Y74.4%
5. Dividend
5.1 Amount
- ARDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.56
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2026-02-19/amc
Earnings (Next)04-29 2026-04-29
Inst Owners67.27%
Inst Owner Change13.57%
Ins Owners2.36%
Ins Owner Change4.38%
Market Cap1.59B
Revenue(TTM)407.32M
Net Income(TTM)-61.60M
Analysts90
Price Target16.2 (146.95%)
Short Float %7.93%
Short Ratio4.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0%
Min EPS beat(2)-100%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)-1.35%
Min EPS beat(4)-100%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)59.25%
EPS beat(12)8
Avg EPS beat(12)48.51%
EPS beat(16)12
Avg EPS beat(16)412.07%
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)3.91%
Max Revenue beat(2)6.56%
Revenue beat(4)3
Avg Revenue beat(4)5.19%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)7
Avg Revenue beat(8)11.24%
Revenue beat(12)10
Avg Revenue beat(12)23.49%
Revenue beat(16)13
Avg Revenue beat(16)23.73%
PT rev (1m)9.3%
PT rev (3m)22.08%
EPS NQ rev (1m)-19.18%
EPS NQ rev (3m)-30.2%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)22.03%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)2.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.84 | ||
| P/S | 3.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.55 | ||
| P/tB | 9.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.25
EYN/A
EPS(NY)0.14
Fwd EY2.18%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.68
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.28% | ||
| ROE | -36.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.29% | ||
| FCFM | N/A |
ROA(3y)-14.49%
ROA(5y)-36.87%
ROE(3y)-33.03%
ROE(5y)-71.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y-1.65%
F-Score3
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 48.77% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.31 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z | 1.46 |
F-Score3
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)41.47%
Cap/Depr(5y)51.91%
Cap/Sales(3y)0.32%
Cap/Sales(5y)3.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y157.24%
EPS Next 2Y120.07%
EPS Next 3Y74.4%
EPS Next 5Y60.74%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y98.4%
Revenue growth 5Y121.91%
Sales Q2Q%7.82%
Revenue Next Year35.32%
Revenue Next 2Y34.72%
Revenue Next 3Y24.52%
Revenue Next 5Y27.17%
EBIT growth 1Y-44.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year223.08%
EBIT Next 3Y125.81%
EBIT Next 5Y82.96%
FCF growth 1Y4.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.19%
OCF growth 3YN/A
OCF growth 5YN/A
ARDELYX INC / ARDX FAQ
What is the ChartMill fundamental rating of ARDELYX INC (ARDX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ARDX.
Can you provide the valuation status for ARDELYX INC?
ChartMill assigns a valuation rating of 3 / 10 to ARDELYX INC (ARDX). This can be considered as Overvalued.
How profitable is ARDELYX INC (ARDX) stock?
ARDELYX INC (ARDX) has a profitability rating of 2 / 10.
Can you provide the financial health for ARDX stock?
The financial health rating of ARDELYX INC (ARDX) is 3 / 10.